GNH USA

Europe — EMA

Octaninef (Human Coagulation Factor Ix)

GNH USA supplies Octaninef (Human Coagulation Factor IX), a coagulation factor IX concentrate for Hemophilia B and acquired factor IX deficiency.

Human Coagulation Factor Ix

Request sourcing

1
Pack/s

What is Human Coagulation Factor Ix?

Human Coagulation Factor IX, the active ingredient in Octaninef, is a coagulation factor IX concentrate presented as a sterile intravenous solution for use in patients with factor IX deficiency. It replaces the missing clotting protein, helping to restore normal haemostasis in hemophilia B and acquired factor IX deficiency. GNH USA supplies Octaninef as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Human Coagulation Factor Ix used for?

Octaninef acts on the intrinsic coagulation pathway to replace deficient factor IX in affected patients. - Hemophilia B: provides factor IX replacement to achieve hemostasis and prevent or control bleeding episodes. - Acquired factor IX deficiency: restores clotting activity to enable normal coagulation. - Surgical procedures in hemophilia B patients: supplies adequate factor IX levels to allow safe operative interventions.

What are the side effects of Human Coagulation Factor Ix?

Octaninef may be associated with infusion‑related and immunologic reactions.

Common Side Effects: - Infusion‑related reactions: chills, fever, or flushing. - Headache. - Nausea. - Arthralgia. - Mild hypotension. - Local site discomfort.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions. - Development of neutralizing inhibitors (antibodies) against factor IX. - Thromboembolic events. - Renal impairment or failure. - Hemolysis. - Disseminated intravascular coagulation (rare).

What precautions apply to Human Coagulation Factor Ix?

Octaninef requires careful clinical monitoring and adherence to handling guidelines. - Dose individualized: dosing is determined by the prescribing clinician based on factor IX activity and clinical need. - Monitor for inhibitor development: regular laboratory testing is recommended. - Avoid in patients with known hypersensitivity to plasma proteins or any excipient. - Use with caution in individuals with a history of thrombosis or cardiovascular disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Human Coagulation Factor Ix interact with?

Octaninef can interact with other agents that affect coagulation.

Major Interactions (Avoid): - Concurrent use of pro‑coagulant agents (e.g., activated prothrombin complex concentrates) may increase thrombosis risk. - Co‑administration with anticoagulants (e.g., warfarin, direct oral anticoagulants) may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs may influence inhibitor formation. - Use with other plasma‑derived products may raise infection transmission concerns. - Timing of vaccinations may need adjustment to avoid overlapping immune activation.

Frequently asked questions

What is Octaninef used for?+
Octaninef is a plasma‑derived coagulation factor IX concentrate indicated for replacement therapy in patients with hemophilia B (factor IX deficiency) and for acquired factor IX deficiency. It is administered intravenously to restore clotting ability and manage bleeding episodes or to provide prophylaxis during surgical procedures.
How does Human Coagulation Factor IX work?+
Human Coagulation Factor IX is a protein component of the intrinsic pathway of the coagulation cascade. When infused, it replaces the missing or deficient factor IX, enabling activation of factor X to Xa, which then leads to thrombin generation and fibrin clot formation, thereby normalizing hemostasis.
What is the usual dose of Octaninef?+
The dose of Octaninef is individualized and determined by the prescribing clinician based on the patient’s baseline factor IX activity, the severity of bleeding, and the intended clinical goal (on‑demand treatment or prophylaxis). The prescriber calculates the required units per kilogram and adjusts according to laboratory monitoring.
Is Octaninef safe in pregnancy or breastfeeding?+
Safety data for Octaninef in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use during pregnancy or while breastfeeding should only be considered when the potential benefit to the mother outweighs any potential risk to the fetus or infant, and it must be prescribed by a specialist.
How do I order Octaninef from GNH USA?+
To order Octaninef, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain handling if needed) and assists with import documentation.
How does Octaninef compare with other factor IX products?+
Octaninef is a plasma‑derived factor IX concentrate, whereas alternative products include recombinant factor IX and extended‑half‑life recombinant variants. Plasma‑derived products contain a broader spectrum of plasma proteins and may have a different immunogenicity profile, while recombinant forms are produced without human plasma and often have longer half‑lives, potentially reducing infusion frequency.
What are the storage and handling requirements for Octaninef?+
Octaninef must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging until use, must not be frozen or shaken, and any unused portion should be discarded according to local regulations after the recommended in‑use period. Proper cold‑chain management is essential during transport.
How is Octaninef administered?+
Octaninef is administered intravenously, typically as a slow infusion into a peripheral or central vein. The infusion rate and volume are determined by the prescribing clinician based on the calculated dose and patient tolerance. Administration should be performed by trained healthcare professionals in a setting where vital signs can be monitored.
What are the most serious risks associated with Octaninef?+
The most serious risks include the development of neutralizing antibodies (inhibitors) against factor IX, which can reduce efficacy, and rare but severe hypersensitivity reactions such as anaphylaxis. Thromboembolic events may also occur, especially if dosing exceeds recommended levels. Patients should be monitored closely for these events during and after infusion.
Who should not use Octaninef?+
Octaninef should not be used in individuals with known hypersensitivity to any component of the product, including human plasma proteins. It is also contraindicated in patients who have experienced severe allergic reactions to previous factor IX concentrates. Use in patients with active disseminated intravascular coagulation should be avoided unless specifically indicated by a specialist.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Human Coagulation Factor Ix
Route
Intravenous Use
Manufacturer
Octapharma Produtos Farmaceuticos, Lda.
Origin
EU

Related products

Aimafix

Aimafix

Human Coagulation Factor Ix

Kedrion S.P.A.
EU
Aimafix

Aimafix

Human Coagulation Factor Ix

Kedrion S.P.A.
EU
Aimafix

Aimafix

Human Coagulation Factor Ix

Kedrion S.P.A.
EU
Alphanine

Alphanine

Human Coagulation Factor Ix

Grifols Deutschland Gmbh
EU